These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35534339)

  • 21. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.
    Maylin S; Martinot-Peignoux M; Ripault MP; Moucari R; Cardoso AC; Boyer N; Giuily N; Castelnau C; Pouteau M; Asselah T; Nicolas-Chanoine MH; Marcellin P
    Liver Int; 2009 Apr; 29(4):511-7. PubMed ID: 19076273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transplantation of liver from hepatitis C-infected donors to hepatitis C RNA-negative recipients: Histological and virologic outcome.
    Nair SP; Marella HK; Maliakkal B; Snyder H; Handley C; Kothadia JP; Ali B; Satapathy SK; Molnar MZ; Clark I; Jain R; Helmick R; Eymard C; Eason JD
    Clin Transplant; 2021 May; 35(5):e14281. PubMed ID: 33690929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
    Sarrazin C; Isakov V; Svarovskaia ES; Hedskog C; Martin R; Chodavarapu K; Brainard DM; Miller MD; Mo H; Molina JM; Sulkowski MS
    Clin Infect Dis; 2017 Jan; 64(1):44-52. PubMed ID: 27737953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
    Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
    Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access.
    Martin MT; Waring N; Forrest J; Nazari JL; Abdelaziz AI; Lee TA
    Public Health Rep; 2023; 138(3):467-474. PubMed ID: 35674245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment.
    Liu CH; Peng CY; Kao WY; Yang SS; Shih YL; Lin CL; Tsai MK; Lee CY; Chang CC; Wu JH; Liu CJ; Su TH; Tseng TC; Chen PJ; Kao JH
    Aliment Pharmacol Ther; 2022 Feb; 55(4):434-445. PubMed ID: 34773272
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection.
    Kuriry H; Casey J; Krassenburg L; La D; Kuczynski M; Shah H; Janssen HLA; Hansen BE; Feld JJ
    Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2398-2406.e1. PubMed ID: 32629131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
    Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
    EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rheumatoid factor and immunoglobulin M mark hepatitis C-associated mixed cryoglobulinaemia: an 8-year prospective study.
    Cheng YT; Cheng JS; Lin CH; Chen TH; Lee KC; Chang ML
    Clin Microbiol Infect; 2020 Mar; 26(3):366-372. PubMed ID: 31229596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three Years of Progress Toward Achieving Hepatitis C Elimination in the Country of Georgia, April 2015-March 2018.
    Tsertsvadze T; Gamkrelidze A; Chkhartishvili N; Abutidze A; Sharvadze L; Kerashvili V; Butsashvili M; Metreveli D; Gvinjilia L; Shadaker S; Nasrullah M; Adamia E; Zeuzem S; Afdhal N; Arora S; Thornton K; Skaggs B; Kuchuloria T; Lagvilava M; Sergeenko D; Averhoff F
    Clin Infect Dis; 2020 Aug; 71(5):1263-1268. PubMed ID: 31563938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
    Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
    J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-based hepatitis C therapy in a safety net hospital: access, efficacy, and safety.
    Nordstrom EM; Keniston A; Baouchi F; Martinez-Camacho A
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):10-16. PubMed ID: 27755117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the COVID-19 pandemic on hepatitis C outcomes at a health-system specialty pharmacy.
    Cooper MP; Foley H; Damico D; Wright M; Rhudy C; Schadler A; Platt T
    J Manag Care Spec Pharm; 2022 Jun; 28(6):667-672. PubMed ID: 35621721
    [No Abstract]   [Full Text] [Related]  

  • 36. Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.
    Welsch C; Efinger M; von Wagner M; Herrmann E; Zeuzem S; Welzel TM; Lange CM
    PLoS One; 2017; 12(2):e0171755. PubMed ID: 28196130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals.
    Gentene AJ; Bell AM; Pence A; Thomas K; Jakubecz C; Stacy E; Woolf B; Guido MR; Mueller EW; Sherman KE
    Ann Pharmacother; 2021 May; 55(5):565-574. PubMed ID: 33016095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
    Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
    Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
    World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.